INMUNE BIO


Associated tags: TNF, Patient, Cancer, NK, Natural killer cell, Inflammation, Disease, Pharmaceutical industry, Medical imaging, Research

Locations: MA, BOSTON, NEWPORT BEACH, CA, NORTH AMERICA, PARK AVENUE, AD, FLORIDA, NEW YORK, ADA

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 2, 2023

BOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update.
  • Q4 2022 and 2022 Corporate Highlights:
    Consolidating the Mild Cognitive Impairment (MCI) Phase 2 trial into the Mild Alzheimer’s Disease Phase 2 study which will become a single Phase 2 AD trial.
  • Received research and development rebates from Australia and the United Kingdom in early 2023 that totaled approximately $6.4 million USD.
  • As of December 31, 2022, the Company had cash and cash equivalents of approximately $52.2 million.

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

Retrieved on: 
Tuesday, February 21, 2023
Conference, Disease, Pharmaceutical industry, Video game

Boca Raton, Florida, Feb. 21, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 2, 2023 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2022 and to provide a corporate update.

Key Points: 
  • Boca Raton, Florida, Feb. 21, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 2, 2023 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2022 and to provide a corporate update.
  • To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
  • Please ask for the INmune Bio Fourth Quarter Conference Call when reaching an operator.

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

Retrieved on: 
Wednesday, February 8, 2023
Disease, BOCA, United Kingdom, AD, Research, FDA, Pharmaceutical industry, Health insurance

BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it has received a combined approximately $6.4 million in research and development refunds from both Australia (~$3.7 million) and the United Kingdom (~$2.7 million).

Key Points: 
  • BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it has received a combined approximately $6.4 million in research and development refunds from both Australia (~$3.7 million) and the United Kingdom (~$2.7 million).
  • The Company will use the rebates to reinvest in its clinical programs, particularly the ongoing Phase 2 Alzheimer’s Disease (AD) trial in Australia and Canada.
  • “The R&D rebates are a non-dilutive source of funding that enable INmune to meaningfully reinvest the proceeds to increase recruitment and enrollment in both Australia where we expect to continue to receive future rebates associated with increased spend and Canada where we are expanding the Phase 2 AD program.
  • We continue to expand our international enrollment and are working diligently on trying to open additional international countries for the Phase 2 AD trial while we continue to collaborate with the FDA and its manufacturing review of the planned U.S. trial,” commented David Moss, Chief Financial Officer.

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

Retrieved on: 
Wednesday, January 25, 2023
Myopathy, Fibrosis, Disease, Liver, TNF, Inflammation, Pathology, CNS, Heart, Intellectual property, CFO, Immune system, Drug development, Patient, University of California, Irvine School of Medicine, Dystrophin, Process control block, DMD, Precision medicine, Muscle atrophy, Duchenne muscular dystrophy, Dentistry, Pharmaceutical industry, University of California

“These data are important because this single drug appears to be decreasing muscle damage while promoting muscle regeneration,” said Prof. Villalta.

Key Points: 
  • “These data are important because this single drug appears to be decreasing muscle damage while promoting muscle regeneration,” said Prof. Villalta.
  • Approved DMD therapies aim to restore dystrophin expression or influence a single pathology of this complex disease, for example chronic inflammation.
  • It is rare to see a single drug provide multiple benefits and even rarer to see muscle regeneration as a key outcome.
  • “Our DN-TNF biologic’s ability to selectively target soluble TNF provides a precision medicine approach to the treatment of DMD,” said RJ Tesi MD, CEO of INmune Bio.

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

Retrieved on: 
Thursday, December 22, 2022
Government, Dementia, Virginia Commonwealth University, Nerve, Associate, Disability, Department of Defense Serum Repository, Traumatic brain injury, Research, Government budget balance, Barrow Neurological Institute, United States Department of Defense, Apolipoprotein E, Inflammation, Alzheimer's disease, VCU, Disease, Patient, Pathology, VCU School of Business, APOE4, TBI, AD, Doctor of Philosophy, VCU School of Medicine, Pharmaceutical industry, Neuroscience, Medicine

Boca Raton, Florida, Dec. 22, 2022 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease in concert with Virgina Commonwealth University (VCU) and Barrow Neurological Institute have received a grant from the Department of Defense (DoD). The grant is titled: Novel solTNF inhibitor improves outcomes in a mouse model of TBI-induced AD. The funding covers a collaboration that studies the impact of traumatic brain injury (TBI) in the development of Alzheimer’s disease (AD) related pathology. These DoD funded studies are a collaboration between Dr. Kirsty Dixon, Associate Professor of Surgery and director of Surgery’s Neurotrauma Repair Laboratory at Virginia Commonwealth University, and Dr. Elliott Mufson, Professor of Neurobiology and the director of the Alzheimer’s disease research laboratory at Barrow Neurological Institute and INmune Bio.

Key Points: 
  • The grant is titled: Novel solTNF inhibitor improves outcomes in a mouse model of TBI-induced AD.
  • The funding covers a collaboration that studies the impact of traumatic brain injury (TBI) in the development of Alzheimer’s disease (AD) related pathology.
  • “This is a great example of collaboration for innovation,” said RJ Tesi MD, CEO of INmune.
  • "This study is an important step toward helping us better understand the relationship between these disorders and to develop effective therapies."

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

Retrieved on: 
Thursday, December 8, 2022
Conference, Breast cancer, Metabolomics, Cell, Society, NK, Clinical trial, Tumor microenvironment, Laurel, Security (finance), Ovarian cancer, Cytokine, Food, MDS, FDA, Proteomics, Marketing, TME, Lymphoma, Cancer, TNF, Inflammation, US Foods, ASH, Vivo, University of Southampton, AML, MD, CSO, Natural killer cell, Research, Disease, Professor, Lymphatic system, Leukemia, Biology, Multiple myeloma, Patient, Pharmaceutical industry, Medical imaging, Vaccine, EU

Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days.

Key Points: 
  • Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days.
  • “The treatment of these patients with advanced hematologic malignancies has produced proof-of-concept data for INKmune while expanding insight into the role of NK cells in controlling cancer,” said Dr. Mark Lowdell, CSO of INmune Bio.
  • Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.
  • The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer.

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

Retrieved on: 
Tuesday, December 6, 2022
Breast cancer, Immunotherapy, Woman, TAM, NK, Comparative oncology, Inflammation, Partnership, Security (finance), Food, Marketing, FDA, US Foods, TME, Cancer, Domination, TNF, MDSC, Trastuzumab, MD, Toxicity, Research, Biomarker, Blood, Patient, Natural killer cell, Pharmaceutical industry

Boca Raton, Florida, Dec. 06, 2022 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on the combination of INB03™ and trastuzumab-deruxtecan (TDxd) for treatment of HER2 positive breast cancer. The data suggests INB03™, a dominant-negative TNF inhibitor that selectively sequesters soluble TNF (sTNF), may provide a novel mechanism for reversing resistance to HER2 targeted immunotherapy, and through this mechanism, may further enhance efficacy and reduce toxicity associated with TDxd treatment in some patients. TDxd is a trastuzumab-based antibody drug conjugate used to treat certain patients with HER2 breast cancer.

Key Points: 
  • “MUC4 expression is an easily determined biomarker that predicts resistance to trastuzumab based immunotherapy.
  • INmune Bio, Inc . is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™).
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Retrieved on: 
Tuesday, November 29, 2022
Marketing, US Foods, AFD, Dementia, Remyelination, Cognitive deficit, Neuroinflammation, MCI, TNF, Food, Natural killer cell, Conference, Probability, Drug development, AD, Patient, Adi, Biomarker, Disease, Inflammation, Security (finance), CDR, RDT, Cancer, Research, Element, White matter, Clinical trial, Biology, FDA, Vaccine, Pharmaceutical industry, Medical imaging

Boca Raton, Florida, Nov. 29, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will participate in the 15th CTAD Conference in San Francisco November 29th to December 2nd.

Key Points: 
  • This years CTAD is showcasing a potential approvable therapy for the treatment of Alzheimers Disease (AD) that targets amyloid, said RJ Tesi MD, CEO of INmune.
  • This will require the incorporation of novel biomarkers into innovative clinical trial designs.
  • Novel, non-invasive neuroimaging biomarkers are used to demonstrate biologic effects of XPro therapy in AD patients with neuroinflammation.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

Retrieved on: 
Monday, November 14, 2022
FDA, AD, Marketing, Clinical trial, Brain, US Foods, Natural killer cell, Remyelination, Health Canada, Cancer, Inflammation, Research, Security (finance), Disease, BOCA, TNF, Food, Patient, Vaccine, Medical device, Pharmaceutical industry

We are pleased that Canada is now part of this international Phase II trial, said Dr. RJ Tesi, CEO of INmune Bio.

Key Points: 
  • We are pleased that Canada is now part of this international Phase II trial, said Dr. RJ Tesi, CEO of INmune Bio.
  • Enrolling patients in both Canada and Australia gives us access to a larger patient population that should help increase the pace of enrollment.
  • The first patient in the Phase 2 trial recently completed all dosing and has enrolled in an open-label extension study in Australia.
  • DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03), Mild Alzheimers disease, Mild Cognitive Impairment and treatment-resistant depression (XPro).

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Retrieved on: 
Wednesday, November 2, 2022
Marketing, Initiate, GLOBE, Brain, Research, BOCA, IND, NIH, Neuroinflammation, PIN, Lymphoma, Private Securities Litigation Reform Act, Company, Review, FDA, Təsi, CMC, TNF, CEO, Trastuzumab, US Foods, Chemistry, TME, ASH, Program, Immunotherapy, Cell, Squamous cell carcinoma, AD, NASDAQ, Neoplasm, U.S. Securities and Exchange Commission, Multiple myeloma, Patient, Ovarian cancer, MCI, Cancer, Natural killer cell, Security (finance), Control, Quarter, SITC, Conference, Clinical trial, TRD, Disease, SAS, ADC, Inflammation, Woman, Better Access Scheme, NK, Antibody-drug conjugate, MUC4, Tumor microenvironment, Breast cancer, Biomarker, Society, Hypoxia, Cytokine, Food, Prostate, Leukemia, Process control block, Vaccine, Pharmaceutical industry, Medical device, Medical imaging, Renewable energy

BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the quarter ended September 30, 2022 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the quarter ended September 30, 2022 and provides a business update.
  • The second UK clinical site is due to be initiated in November 2022 and a third UK site is under evaluation.
  • Financial Results for the Quarter Ended September 30, 2022:
    Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.
  • Other expense was approximately $0.3 million for the quarter ended September 30, 2022 compared to approximately $0.4 million during the quarter ended September 30, 2021.